Home > Keywords > Thématique > Science

Science

Articles

  • New PCT patent application covering anti Transferrin receptor vectors
    13 October 2020, by Elodie DORMES

    Vect-Horus has filed a PCT patent application covering a library of vectors that target the Transferrin receptor (TfR). This patent strengthens the intellectual property of the Company with a portfolio containing now 6 patent families. This confirms its position as a major player in Blood-Brain Barrier drug delivery technology.

  • Vect-Horus will participate to the “R&D Seminar IMAGING 2022” organized by the Cerimed September 26-30, 2022
    26 September 2022, by Elodie DORMES

    VECT-HORUS S.A.S. will participate in the next event dedicated to Imaging and organized by CERIMED: “R&D Seminar IMAGING 2022” from Monday, 26th September to Friday 30th September.
    Cedric MALICET will give a talk, « From bench to Clinic », Thursday, 29th September in the workshop intitled “NUCLEAR MEDICINE Imaging”.
    It will be the occasion to present Vect-Horus technology, the last imaging results generated by in vitro and in vivo TEP with our #LDLR vectors currently in clinical study (…)

  • Vect-Horus demonstrates the high versatility of its peptide-vectors library for a targeted delivery of small molecules and protein cargos
    28 January 2019, by Jonathan NOWAK

    Identification and characterization of highly versatile peptide-vectors that bind non-competitively to the low-density lipoprotein receptor for in vivo targeting and delivery of small molecules and protein cargos.
    Marion David, Pascaline Lécorché, Maxime Masse, Aude Faucon, Karima Abouzid, Nicolas Gaudin, Karine Varini, Fanny Gassiot, Géraldine Ferracci, Guillaume Jacquot, Patrick Vlieghe, Michel Khrestchatisky
    http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0191052 (…)

  • 3rd Edition of Translational neuroscience Day : challenges and opportunities
    4 December 2019, by Elodie DORMES

    Michel KHRESTCHATISKY co-founder of Vect-Horus – Director of the UMR7051 Institute of Neurophysiopathology at Aix-Marseille University / CNRS will speak at two sessions of The third edition of “Translational neuroscience Day: challenges and opportunities” co-organized by Dhune and hosted by BioFIT on December 10, 2019.

  • Vect-Horus appoints Dr Jamal Temsamani as Director of Drug Development & Corporate
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS announced today the appointment of Dr. Jamal Temsamani as Director in charge of Drug Development & Corporate. He will lead the Company’s drug development programs from discovery to early clinical and will be in charge of industrial partnerships. Dr. Jamal Temsamani is also a member of the Management Committee of VECT-HORUS.

  • TIDES Europe: Oligonucleotide & Peptide Therapeutics in AMSTERDAM
    31 October 2019, by Elodie DORMES

    Dr Guillaume JACQUOT will present "Targeted Drug Delivery to the CNS and Peripheral Tissues Using the VECTrans® Innovative Technology" during the TIDES Europe, 12-15 November 2019.

  • Two new patents protecting VECTrans® technology issued in several major countries
    28 January 2019, by Jonathan NOWAK

    Press release Communiqué de presse
    VECT-HORUS, a biotechnology company that designs and develops peptide vectors for addressing drugs or imaging agents to the brain and other organs, announces the strengthening of its patent portfolio with the granting of two patents in several major countries and particularly in the United States.
    These two patents protect peptide vectors that facilitate the targeting of drugs or imaging agents to organs, including the brain. Entitled “Peptide (…)

  • Vect-Horus and RadioMedix Announce FDA Approval of Exploratory IND of Diagnostic 68 Ga-RMX-VH in Glioblastoma Multiforme
    8 July 2021, by Elodie DORMES

    Vect-Horus and RadioMedix are pleased to announce the FDA clearance of eIND application to evaluate 68Ga-RMX-VH for the diagnostic of GBM.

  • Poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
    15 May 2024, by Emmanuelle BETTENDORF

    The poster, entitled “VECTrans® technology: a powerful delivery approach to significantly enhance efficacy of therapeutic oligonucleotides in retina cells”, outlines a study assessing Vect-Horus’ proprietorial VECTrans® technology. This is based on the specific design and optimization of molecular vectors that, once joined to a payload, enable its delivery to target specific organs in the body.
    The study showed that these vectors have the potential to improve delivery of medication to the (…)

  • Meet Vect-Horus at OTS, Barcelona, October 22-25, 2023
    12 October 2023, by Emmanuelle BETTENDORF

    Vect-Horus team will attend the 19th Annual Meeting of the Oligonucleotide Therapeutics Society from October 22nd to 25th, 2023, in Barcelona.
    We are pleased to announce that Guillaume Jacquot, Program Director, Brain & Tissue Targeting of Oligonucleotides, will give a talk entitled “TfR-targeted functional delivery of oligonucleotides to CNS tissues by local and systemic administration” on Tuesday, 24th and Emmanuelle Bettendorf, Senior Business Developer, will also be there and (…)